Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
Hypersensitivities01:30

Hypersensitivities

519
Hypersensitivity, also known as a hypersensitivity reaction or allergic reaction, is a condition where the body's immune system reacts abnormally to a foreign substance. Such substances, that cause hypersensitivity are referred to as an allergen, could be something typically harmless to most people, like pollen or certain foods.
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
519
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
245
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

113
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
113
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

352
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
352

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-Life Effectiveness and Safety of Lebrikizumab in Elderly Patients with Atopic Dermatitis: A Multicenter Study.

Clinical and experimental dermatology·2026
Same author

Complement and transplant-associated thrombotic microangiopathy: Current and future approaches.

HemaSphere·2026
Same author

Exercise-induced vasculitis with histological and genetic evidence of complement involvement.

Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG·2026
Same author

Real-World Effectiveness and Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A 52-Week Retrospective Italian Study Focusing on Head and Neck Involvement.

Dermatology and therapy·2026
Same author

D-Dimer Elevation in Spontaneous Urticaria and Bullous Pemphigoid, Two Chronic Inflammatory Skin Diseases.

American journal of hematology·2026
Same author

Algorithms in Allergy: Diagnosis and Treatment of Pollen Food Syndrome.

Allergy·2026

Related Experiment Video

Updated: Jun 6, 2025

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

411

Therapies for Chronic Spontaneous Urticaria: Present and Future Developments.

Riccardo Asero1, Paolo Calzari2, Silvia Vaienti3

  • 1Clinica San Carlo, Ambulatorio di Allergologia, 20037 Paderno Dugnano, Italy.

Pharmaceuticals (Basel, Switzerland)
|November 27, 2024
PubMed
Summary

Chronic spontaneous urticaria (CSU) treatment is evolving beyond antihistamines and omalizumab. New therapies targeting Bruton

Keywords:
CDX-0159EP 262TAS 5315TLL-018TezepelumabUB-221antihistaminesbarzolvolimabchronic spontaneous urticariacorticosteroidscyclosporindupilumabmepolizumabomalizumabpovorcitinibremibrutinibrilzabrutinibvixarelimab

More Related Videos

Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

8.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

Related Experiment Videos

Last Updated: Jun 6, 2025

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

411
Basophil Activation Test for Allergy Diagnosis
07:22

Basophil Activation Test for Allergy Diagnosis

Published on: May 31, 2021

8.1K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

38.9K

Area of Science:

  • Immunology and Dermatology
  • Pharmacology and Therapeutics

Background:

  • Chronic spontaneous urticaria (CSU) significantly impacts quality of life, characterized by recurrent wheals and angioedema.
  • Current European guidelines recommend escalating doses of second-generation H1-antihistamines (sgAHs) followed by omalizumab for refractory cases.
  • A subset of CSU patients remains unresponsive to existing treatments, highlighting the need for novel therapeutic strategies.

Purpose of the Study:

  • To review emerging therapeutic targets and novel treatments for difficult-to-treat chronic spontaneous urticaria.
  • To explore the potential of new drugs targeting key immune pathways in CSU management.

Main Methods:

  • Review of current treatment guidelines for CSU.
  • Exploration of novel therapeutic targets including Bruton's tyrosine kinase (BTK), IL-4/IL-13 pathways, MRGPRX2, and Kit tyrosine kinase.
  • Analysis of promising investigational drugs such as remibrutinib, dupilumab, and barzolvolimab.

Main Results:

  • Investigational drugs targeting BTK, IL-4/IL-13, MRGPRX2, and Kit show promise in clinical studies.
  • These novel therapies aim to reduce mast cell activation and modulate key immune pathways involved in CSU.
  • Emerging treatments offer potential for improved efficacy in patients refractory to standard therapies.

Conclusions:

  • The future of CSU treatment lies in targeting specific pathogenetic mechanisms.
  • New therapies hold promise for achieving longer-term remission and improving outcomes for patients with refractory CSU.
  • Further research is crucial to optimize treatment protocols and understand the long-term benefits of these emerging therapies.